CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464600503
- Phone
- 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- 4 Open-market sale Chief Legal Officer sold 6,844 shares at $14.52 ($99,378)
- S-8 Other Securities Offered to Employees in Benefit Plans
- S-3ASR Offering Registration Statement
- 10-K Report Annual Report
- 8-K Event Results of operations
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Open-market sale Chief Legal Officer sold 3,419 shares at $14.14 ($48,352)
- 144 Insider Sale of Securities
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Open-market sale Chief Financial Officer sold 3,557 shares at $14.65 ($52,097)
- 4 Open-market sale Co-Chief Executive Officer sold 15,500 shares at $14.68 ($227,593)
- 4 Open-market sale Chief Legal Officer sold 3,448 shares at $14.65 ($50,516)
- 4 Open-market sale Co-Chief Executive Officer sold 15,500 shares at $14.69 ($227,618)
- 144 Insider Sale of Securities
Page 4 of 23 · 446 filings